Seres Therapeutics, Inc.

MCRB

US81750R1023

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.825 ^USD	+11.08%		+47.35%	-41.07%

Apr. 26	Foreign automakers eager for Chinese partners at Beijing auto show	RE
Apr. 25	Battle for 'tech luxury' in China as EVs get smarter - and cheaper	RE

Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from S&P Biotechnology Select Industry Index

December 18, 2023 at 12:00 am EST

Latest news about Seres Therapeutics, Inc.

Foreign automakers eager for Chinese partners at Beijing auto show	Apr. 26	RE
Battle for 'tech luxury' in China as EVs get smarter - and cheaper	Apr. 25	RE
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT	Apr. 09	CI
Declaration of Voting Results by Seres Therapeutics	Apr. 08	CI
Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating	Mar. 06	MT
Chardan Cuts Price Target on Seres Therapeutics to $8 From $10 on Higher Expected Sharecount Dilution, Keeps Buy Rating	Mar. 06	MT
Seres Therapeutics Files a Definitive Proxy Statement with Securities and Exchange Commission	Mar. 05	CI
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Transcript : Seres Therapeutics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
North American Morning Briefing : S&P 500 Futures -2-	Mar. 05	DJ
Seres Therapeutics, Inc. Announces Chief Financial Officer Changes	Feb. 26	CI
Seres Therapeutics Appoints Marella Thorell as Executive Vice President	Feb. 26	CI
Kenneth Steiner Submits a Shareholder Proposal to Seres Therapeutics	Feb. 23	CI
Oppenheimer Trims Seres Therapeutics Price Target to $9 From $10, Maintains Outperform Rating	Jan. 16	MT
Transcript : Seres Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM	Jan. 10
Seres Therapeutics Shares Rise 15% After Getting FDA Fast-Track Designation for Infection Treatment	Jan. 09	DJ
Seres Therapeutics Announces VOWST? Commercial Launch Update and US FDA Fast Track Designation for SER-155	Jan. 09	CI
Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from S&P Biotechnology Select Industry Index	Dec. 18	CI
Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Huawei's new smart car firm valued up to $35 bln amid advanced stake talks -sources	Nov. 29	RE
Goldman Sachs Adjusts Price Target on Seres Therapeutics to $1.25 From $4, Maintains Sell Rating	Nov. 03	MT
Oppenheimer Adjusts Seres Therapeutics Price Target to $10 From $12, Maintains Outperform Rating	Nov. 03	MT
Transcript : Seres Therapeutics, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Earnings Flash (MCRB) SERES THERAPEUTICS Reports Q3 Revenue $310,000, vs. Street Est of $850,000	Nov. 02	MT
Seres Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI

Chart Seres Therapeutics, Inc.

Duration

Period

More charts

Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Seres Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.825 USD

Average target price

7.22 USD

Spread / Average Target

+775.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SERES THERAPEUTICS, INC.	-41.07%	125M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs